ABBV (AbbVie Inc.) financial statements and key performance indicators

AbbVie Inc.

ABBV

232.36 (0.40%) 0.92

Health Care

Biotechnology

AbbVie Inc. a research-based biopharmaceutical company engages in the research and development manufacture commercialization and sale of medicines and therapies worldwide. The company offers Humira an injection for autoimmune and intestinal Behçet's diseases generalized pustular psoriasis and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases erythrodermic psoriasis generalized pustular psoriasis and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables plastics and regenerative medicine body contouring and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia bipolar disorder and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine as well as other neuroscience products. In addition the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago Illinois.

Quality Checklist 1/8

Est. EPS Growth > 5%

5Y Shares Out Change < 0%

ROIC > 10%

Debt/Equity < 1

Current Ratio > 1

Quick Ratio > 1

Net Margin > 10%

Past Net Income CAGR > 0%

0.0%of Portfolio

My holdings

Day change:

Total change:

Cost basis:

Market cap: $410.67(B)

EV: $473.89(B)

Total Equity: $-2.60(B)

Earnings date: Jan-30-2026

P/E: 174.71

Forward P/E: 21.84

P/FCF: 20.86

P/S: 6.89

P/B: N/A

EPS: $1.3

EPS (fwd): $10.6

FCF/share: $11.1

Revenue/share: $33.7

Book value/share: $-1.5

ROIC: 3.3%

ROA: 1.7%

ROE: 140.9%

Debt/Equity: 48

Current Ratio: 0.70

Gross margin: 71.5%

Operating margin: 24.1%

Net margin: 4.0%

Dividend/share: $6.6

Div. yield: 2.82%

All Valuation Overview Growth Financials & KPIs Competitors & Peer Comparison Ownership Tools

Historical Financials

Showing limited histrical data.

Upgrade to access 10+ years of financials!

TTM (Y)TTM (Q)FYFQ

Income(show more...)

Revenue Operating Income Net IncomeCOGSGross ProfitTotal OpEx.R&DSG&AInterest ExpenseInterest IncomeOther Non-operating IncomePre-tax incomeIncome tax

Cash flow(show more...)

Stock-based Comp. FCFCFONet IncomeD&AChange in Working CapitalCFFStock IssuedStock RepurchasedDebt IssuedDebt RepaidDividend PaidCFIAcquisitionsDivestituresCapital Expenditures

Balance sheet(show more...)

Total Assets Total LiabilitiesCurrent assetsCash and EquivalentsShort-term investmentsInventoriesReceivablesNon-current assetsNet PP&EIntangible AssetsGoodwillCurrent liabilitiesShort-Term DebtAccounts payableNon-current liabilitiesLong-Term DebtTotal Equity